Viatris Inc. (NASDAQ:VTRS) is among the 10 Best Pharma Stocks to Buy According to Billionaires, formed from the merger of Mylan and Pfizer’s Upjohn division. VTRS achieved FDA approval for its first generic Iron Sucrose Injection, USP, a complex generic version of Venofer, strengthening its injectable portfolio. The company reported strong Q2 2025 results, exceeding expectations with revenues of $3.58 billion and adjusted EPS of $0.62, returning over $630 million to shareholders year-to-date. VTRS also made leadership and organizational enhancements, appointing Andrew Enrietti as Chief Administrative and Transformation Officer and adding David Simmons to the board. Pipeline progress continues with positive outcomes from five Phase 3 studies.

Read more at Yahoo Finance: Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection